Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A, Fleeman N, Houten R, Chaplin M, Boland A, Beale S, Dundar Y, McEntee J, Syndikus I. Stainthorpe A, et al. Among authors: chaplin m. Pharmacoecon Open. 2020 Dec;4(4):563-574. doi: 10.1007/s41669-020-00203-0. Pharmacoecon Open. 2020. PMID: 32207075 Free PMC article. Review.
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Houten R, Fleeman N, Mahon J, Chaplin M, Edwards K, Beale S, Boland A, Dundar Y, Marsden A, Malik Z, Palmieri C. Houten R, et al. Among authors: chaplin m. Pharmacoecon Open. 2023 May;7(3):345-358. doi: 10.1007/s41669-023-00405-2. Epub 2023 Apr 21. Pharmacoecon Open. 2023. PMID: 37084172 Free PMC article. Review.
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bresnahan R, Houten R, Greenhalgh J, Nevitt S, Mahon J, Beale S, Boland A, Bhattacharyya D, Dundar Y, McEntee J, Gandhi S, Fleeman N, Chaplin M. Bresnahan R, et al. Among authors: chaplin m. Pharmacoecon Open. 2023 Jul;7(4):525-536. doi: 10.1007/s41669-023-00408-z. Epub 2023 May 17. Pharmacoecon Open. 2023. PMID: 37195551 Free PMC article. Review.
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.
Chaplin M, Bresnahan R, Fleeman N, Mahon J, Houten R, Beale S, Boland A, Dundar Y, Marsden A, Munot P. Chaplin M, et al. Pharmacoecon Open. 2023 Nov;7(6):863-875. doi: 10.1007/s41669-023-00439-6. Epub 2023 Sep 20. Pharmacoecon Open. 2023. PMID: 37731145 Free PMC article. Review.
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
Bresnahan R, Duarte R, Mahon J, Beale S, Chaplin M, Bhattacharyya D, Houten R, Edwards K, Nevitt S, Maden M, Boland A. Bresnahan R, et al. Among authors: chaplin m. Health Technol Assess. 2023 Jul;27(10):1-115. doi: 10.3310/KGJU3398. Health Technol Assess. 2023. PMID: 37839810 Free PMC article.
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.
Chaplin M, Bresnahan R, Fleeman N, Mahon J, Houten R, Beale S, Boland A, Dundar Y, Marsden A, Munot P. Chaplin M, et al. Pharmacoecon Open. 2023 Nov;7(6):1015. doi: 10.1007/s41669-023-00462-7. Pharmacoecon Open. 2023. PMID: 38051493 Free PMC article. No abstract available.
201 results